Replies to post #205339 on Biotech Values

[DewDiligence]

While elucidating the case for being long BMY, let’s not forget the monster growth of Eliquis:

Interesting slide from $JNJ earnings presentation, showing just how competitive new bloodthinner market is now. $PFE $BMY $JNJ pic.twitter.com/IsGEmYhq7C

— Jonathan Rockoff (@jonathanrockoff) October 18, 2016